Cardiovascular

Cardiovascular disease is a leading public health threat that affects nearly 240 million people worldwide.¹ And the number of patients keeps growing. There are many potential causes of cardiovascular disease, yet 80% of cardiovascular events, like heart attacks and strokes, are preventable.² All patients deserve focused approaches to treat their unique conditions.

Amgen is a pioneer in cardiovascular research, with a legacy of addressing unmanaged LDL cholesterol (LDL-C), one of the most modifiable risk factors for heart attack and stroke. Building on this expertise, Amgen continues to push the boundaries of lipid science by expanding research into other critical areas like lipoprotein(a) - also known as Lp(a) - an emerging cardiovascular risk marker.

We are also committed to working with the cardiovascular disease community to achieve the bold ambition of cutting in half the number of heart attacks and strokes in the U.S. by 2030.

Cardiovascular

Bringing Cardiovascular Care to the Heart of Communities

❮1 / 5❯

Cardiovascular

Amgen Expands No Cost Cholesterol Testing Program to Help Address Leading Public Health Crisis

❮2 / 5❯

Cardiovascular

Customized Initiatives Tackling Cardiovascular Disease Across Four Continents

❮3 / 5❯

Cardiovascular

Understanding Cardiovascular Risk: The Role of LDL-C, Comorbidities and Early Intervention

❮4 / 5❯

Cardiovascular

Empowering Change: Addressing Cardiovascular Risk in Underserved Communities Through Clinical Research

❮5 / 5❯

Cardiovascular Disease Areas

Low-density Lipoprotein Cholesterol

LDL cholesterol, often called "bad" cholesterol is one of the most important modifiable factors in reducing a person’s risk of heart disease. LDL cholesterol causes buildup of plaque in the arteries, potentially leading to a heart attack or stroke.

Lipoprotein(a)

Commonly called Lp(a) (or "LP little a") this type of lipoprotein is "stickier" than other types of lipoproteins, making it more likely to cause blockages in the arteries. Unlike LDL cholesterol, high Lp(a) is almost entirely determined by genetics, and lifestyle changes like diet and exercise cannot reduce Lp(a).

Obesity

Excessive accumulations of body fat often have biologic and genetic factors that increase the risk of other serious diseases, including heart disease, heart attack and stroke.

Conversations with the Community

The Power of Patient Stories and Advocacy in Addressing Health Equity Challenges

Every Patient Counts, Every Story Matters: Jeff and Dr. Ravi Salgia

Harnessing the Power of Collaborations to Improve Cardiovascular Health

Pipeline

Amgen has created a robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illnesses.

LEARN MORE

References

Tsao, C. W., Aday, A. W., Almarzooq, Z., Alonso, A., Beaton, A., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., Elkind, M. S., Evenson, K. R., Eze-Nliam, C., Ferguson, J. F., Generoso, G., Ho, J. E., Kalani, R., Khan, S. S., Kissela, B. M., . . . Martin, S. S. (2022). Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation, 145(8). https://doi.org/10.1161/cir.0000000000001052
World Health Organization. Cardiovascular diseases: Avoiding heart attacks and strokes. https://www.who.int/news-room/questions-and-answers/item/cardiovascular-diseases-avoiding-heart-attacks-and-strokes. Accessed July 2023.